{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "8991957", "DateCompleted": {"Year": "1997", "Month": "01", "Day": "16"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0163-3864", "JournalIssue": {"Volume": "59", "Issue": "2", "PubDate": {"Year": "1996", "Month": "Feb"}}, "Title": "Journal of natural products", "ISOAbbreviation": "J Nat Prod"}, "ArticleTitle": "Squamotacin: an annonaceous acetogenin with cytotoxic selectivity for the human prostate tumor cell line (PC-3).", "Pagination": {"StartPage": "97", "EndPage": "99", "MedlinePgn": "97-9"}, "Abstract": {"AbstractText": ["The bark extracts of Annona squamosa yielded a new bioactive acetogenin, squamotacin (1), and the known compound, molvizarin (2), which is new to this species. Compound 1 is identical to the potent acetogenin, bullatacin (3), except that the adjacent bistetrahydrofuran (THF) rings and their flanking hydroxyls are shifted two carbons toward the gamma-lactone ring. Compound 1 showed cytotoxic selectively for the human prostate tumor cell line (PC-3), with a potency of over 100 million times that of Adriamycin."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, Indiana 47907-1333, USA."}], "LastName": "Hopp", "ForeName": "D C", "Initials": "DC"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Zeng", "ForeName": "L", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Gu", "ForeName": "Z", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "McLaughlin", "ForeName": "J L", "Initials": "JL"}], "GrantList": [{"GrantID": "CA30909", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, U.S. Gov't, P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Nat Prod", "NlmUniqueID": "7906882", "ISSNLinking": "0163-3864"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "squamotacin"}, {"RegistryNumber": "OL659KIY4X", "NameOfSubstance": "4-Butyrolactone"}], "MeshHeadingList": [{"QualifierName": ["analogs & derivatives", "isolation & purification", "pharmacology"], "DescriptorName": "4-Butyrolactone"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "isolation & purification", "pharmacology"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Artemia"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Colonic Neoplasms"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Kidney Neoplasms"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pancreatic Neoplasms"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Prostatic Neoplasms"}, {"QualifierName": [], "DescriptorName": "Tumor Cells, Cultured"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1996", "Month": "2", "Day": "1"}, {"Year": "1996", "Month": "2", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1996", "Month": "2", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["8991957", "10.1021/np960124i", "np960124i"]}}]}